Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A1 | P46059 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | MC3R | P41968 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7607313 | 1.00 | SLC15A1 (0.49) | SLC15A1CYP3A4MAPK1CTRB1CYP1A2 | |
| SCHEMBL7607306 | 0.87 | SLC15A1 (0.47) | SLC15A1CYP3A4CTRB1CYP1A2CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL7608053 | 0.85 | SLC15A1 (0.45) | SLC15A1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL7413892 | 0.85 | SLC15A1 (0.45) | SLC15A1CYP3A4CYP1A2CYP2D6CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL7405960 | 0.80 | MMP3 (0.48) | SLC15A1 | |
| Trifluoroacetic Acid SCHEMBL7606327 | 0.80 | MMP3 (0.48) | SLC15A1 | |
| SCHEMBL9752001 | 0.79 | MAPK1 (0.62) | SLC15A1CYP3A4MAPK1MC4RMC3R | |
| SCHEMBL27182846 | 0.79 | MAPK1 (0.62) | SLC15A1CYP3A4MAPK1MC4RMC3R | |
| SCHEMBL7457031 | 0.79 | MAPK1 (0.62) | SLC15A1CYP3A4MAPK1MC4RMC3R | |
| SCHEMBL24453079 | 0.79 | MAPK1 (0.69) | SLC15A1CYP3A4MAPK1MC4RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6495699-B2 | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | AGOURON PHARMACEUTICALS INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | BENDER STEVEN L (US) | 2002-02-14 | — | — | US | disclosed |
| US-6306892-B1 | ENZYME INHIBITORS HETEROCYCLIC AMIDES | AGOURON PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6174915-B1 | FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY | AGOURON PHARMACEUTICALS, INC. | 2001-01-16 | — | — | US | disclosed |
| US-6008243-A | AN ENZYME INHIBITOR FOR PREVENTING THE DEGRADATION AND REMODELING OF CONNECTIVE TISSUES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | MMP9, MMP2, MMP3 | SLC15A1 1953/4885CYP3A4 692/4885MAPK1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.